The report "HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028", is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period. The neurovascular devices market is mainly driven by rising incidence of neurovascular diseases, availability of medical reimbursements for neurovascular procedures, expansion of healthcare infrastructure across emerging economies, increased focus of players on boosting the research in novel neurovascular devices, and growing demand for minimally invasive surgical procedures.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
The molecular assay technologies segment accounted
for the largest share of 86.5% in 2022, by technology segment.
Based on technology, the HLA typing market is
segmented into molecular assay technologies and non-molecular assay
technologies. The molecular assay technologies segment accounted for the
largest market share in 2022. The large share of the segment is attributed to
the benefits of molecular assay technologies over non-molecular assays, such as
low turnaround times, high procedural efficacy, multi-sample study
capabilities, and real-time sample analysis.
Molecular assay techniques are used in HLA typing
for applications such as donor-recipient cross-matching, cancer and autoimmune
disease diagnostics, infectious disease diagnostics, and transfusion.
This market is segmented into PCR-based molecular
assays and sequencing-based molecular assays. The growing demand for molecular
assays is mainly attributed to their technological benefits over non-molecular
assays, such as low turnaround times, high procedural efficacy, and real-time
sample analysis. Other factors supporting market growth include growing
applications in patient profiling, rising public-private investments for
product development, and increasing evidence for the clinical efficacy of
molecular assay techniques, coupled with rising technological advancements in
molecular diagnostics (such as PCR and NGS).
The diagnostic applications segment is anticipated to
register highest CAGR during the forecast period.
Based on application, the diagnostic applications
market is segmented into Donor Recipient Cross Match, Cancer Diagnosis &
Prevention, Infectious & Non-infectious disease testing, Transfusion
Therapy and Others. The diagnostic applications segment accounted for the
highest CAGR of 6.5% during the forecasr period . The diagnostic applications
segment is also projected to grow at the highest CAGR during the forecast
period owing to the rising technological advancements in molecular assay
techniques; increasing adoption of molecular assays for pathogen testing in
infectious and non-infectious disease testing; and the growing incidence of
chronic and infectious diseases.
North America to dominate the global neurovascular
devices market
Based on the region, the neurovascular devices
market is segmented into North America, Europe, Asia Pacific, Latin America and
Middle East & Africa. North America accounted for the largest share of
neurovascular devices market. The large share of North America can be
attributed to the high adoption of HLA typing devices in the region, the strong
presence of companies operating in the market, and the availability of
significant R&D investments for product development.
Request For Customization:- https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=39129877
Asia Pacific is expected to grow at the highest CAGR
during the forecast period owing to the presence of a large target patient
population, rising awareness on the advantages HLA typing, geographical expansion
of players in region, and government initiatives to modernize & expand
healthcare infrastructure.
Major players in neurovascular devices market
include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd.
(Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US),
and bioMérieux S.A. (France). Other players in the market are Immucor, Inc.
(US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton,
Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna
(UK), among others.
No comments:
Post a Comment